Last reviewed · How we verify
Comparator: glipizide
Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Comparator: glipizide |
|---|---|
| Also known as | Glipizide |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Meglitinide (rapid-acting insulin secretagogue) |
| Target | ATP-sensitive potassium channel (KATP channel) / Sulfonylurea receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glipizide is a meglitinide-class insulin secretagogue that binds to sulfonylurea receptors on the ATP-sensitive potassium channels in pancreatic beta cells. This binding closes the potassium channels, leading to cell depolarization and opening of voltage-gated calcium channels, which triggers insulin release. It is used to lower blood glucose in type 2 diabetes by increasing endogenous insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Dizziness
- Headache
- Nervousness
- Tremor
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) (PHASE3)
- Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) (PHASE3)
- An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) (PHASE3)
- MK0767 Glipizide Comparator Cardiac Safety Study (0767-018) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |